Hormonal
Chronic cold exposure induces white-to-brown adipocyte transdifferentiation, increasing energy expenditure and protecting against obesity and type 2 diabetes.
Exposure to cold temperatures can trigger your body to convert energy-storing white fat into energy-burning brown-like fat (beige fat). This process increases your metabolic rate and helps protect against obesity and type 2 diabetes. While you don't need to freeze yourself, understanding this mechanism highlights the importance of factors like exercise (which releases irisin) and potentially cold exposure in managing metabolic health. Future treatments may target these pathways pharmacologically.
This phenotypic change has proved to be effective in the protection against the metabolic disorders associated to obesity and diabetes... animals with abundant natural (18) or induced (39,40) BAT are resistant to obesity and that the administration of drugs that expand BAT is sufficient to curb obesity and related disorders in rats (41,42).
Why this rating
Strong evidence in rodent models (knockout mice, transgenic lines), but human trials of beta3AR agonists failed, indicating translational gaps.
Source
The adipose organ: white‐brown adipocyte plasticity and metabolic inflammation
Arianna Smorlesi et al. · Obesity Reviews · 2012
DOI 10.1111/j.1467-789x.2012.01039.x
More from this paper
- Hypertrophic white adipocytes in obesity trigger chronic low-grade inflammation via macrophage infiltration, contributing to insulin resistance.Good
- Physical exercise induces white-to-brown adipose tissue conversion via the release of irisin and natriuretic peptides, offering a metabolic benefit independent of cold exposure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →